Literature DB >> 26985738

Highly efficient generation of glutamatergic/cholinergic NT2-derived postmitotic human neurons by short-term treatment with the nucleoside analogue cytosine β-D-arabinofuranoside.

Imanol González-Burguera1, Ana Ricobaraza2, Xabier Aretxabala3, Sergio Barrondo4, Gontzal García del Caño5, Maider López de Jesús6, Joan Sallés7.   

Abstract

The human NTERA2/D1 (NT2) cells generate postmitotic neurons (NT2N cells) upon retinoic acid (RA) treatment and are functionally integrated in the host tissue following grafting into the rodent and human brain, thus representing a promising source for neuronal replacement therapy. Yet the major limitations of this model are the lengthy differentiation procedure and its low efficiency, although recent studies suggest that the differentiation process can be shortened to less than 1 week using nucleoside analogues. To explore whether short-term exposure of NT2 cells to the nucleoside analogue cytosine β-d-arabinofuranoside (AraC) could be a suitable method to efficiently generate mature neurons, we conducted a neurochemical and morphometric characterization of AraC-differentiated NT2N (AraC/NT2N) neurons and improved the differentiation efficiency by modifying the cell culture schedule. Moreover, we analyzed the neurotransmitter phenotypes of AraC/NT2N neurons. Cultures obtained by treatment with AraC were highly enriched in postmitotic neurons and essentially composed of dual glutamatergic/cholinergic neurons, which contrasts with the preferential GABAergic phenotype that we found after RA differentiation. Taken together, our results further reinforce the notion NT2 cells are a versatile source of neuronal phenotypes and provide a new encouraging platform for studying mechanisms of neuronal differentiation and for exploring neuronal replacement strategies.
Copyright © 2016 University of Texas at Austin Dell Medical School. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytosine β-d-arabinofuranoside; Neuronal differentiation; Neurotransmitter phenotype; Pluripotent NT2 cells; Postmitotic human neurons; Retinoic acid

Mesh:

Substances:

Year:  2016        PMID: 26985738     DOI: 10.1016/j.scr.2016.02.038

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  5 in total

1.  Analysis of regeneration- and myelination-associated proteins in human neuroma in continuity and discontinuity.

Authors:  Patrick Dömer; Bettina Kewitz; Christian P G Heinen; Ulrike Janssen-Bienhold; Thomas Kretschmer
Journal:  Acta Neurochir (Wien)       Date:  2018-04-14       Impact factor: 2.216

Review 2.  Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism.

Authors:  Sabine Jung-Klawitter; Thomas Opladen
Journal:  J Inherit Metab Dis       Date:  2018-07-06       Impact factor: 4.982

3.  Data for the morphometric characterization of NT2-derived postmitotic neurons.

Authors:  Imanol González-Burguera; Ana Ricobaraza; Xabier Aretxabala; Sergio Barrondo; Gontzal García Del Caño; Maider López de Jesús; Joan Sallés
Journal:  Data Brief       Date:  2016-04-13

4.  Rewiring of the Human Mitochondrial Interactome during Neuronal Reprogramming Reveals Regulators of the Respirasome and Neurogenesis.

Authors:  Mohamed Taha Moutaoufik; Ramy Malty; Shahreen Amin; Qingzhou Zhang; Sadhna Phanse; Alla Gagarinova; Mara Zilocchi; Larissa Hoell; Zoran Minic; Maria Gagarinova; Hiroyuki Aoki; Jocelyn Stockwell; Matthew Jessulat; Florian Goebels; Kirsten Broderick; Nichollas E Scott; James Vlasblom; Gabriel Musso; Bhanu Prasad; Eleonora Lamantea; Barbara Garavaglia; Alex Rajput; Kei Murayama; Yasushi Okazaki; Leonard J Foster; Gary D Bader; Francisco S Cayabyab; Mohan Babu
Journal:  iScience       Date:  2019-09-04

5.  Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.

Authors:  Shiori Ando; Shunya Suzuki; Shoichi Okubo; Kazuki Ohuchi; Kei Takahashi; Shinsuke Nakamura; Masamitsu Shimazawa; Koji Fuji; Hideaki Hara
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.